136 related articles for article (PubMed ID: 26191484)
1. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.
Calisti G; Tavares A; Macartney MJ; McCormick A; Labbett W; Jacobs M; Dusheiko G; Rosenberg WM; Haque T
Springerplus; 2015; 4():357. PubMed ID: 26191484
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.
Derbala M; Rizk NM; Al-Kaabi S; John A; Sharma M; El-dweik N; Yakoob R; Pasic F; Almohanadi M; Alejji K; Abdelmola A; Butt M
Virology; 2013 Sep; 444(1-2):292-300. PubMed ID: 23866096
[TBL] [Abstract][Full Text] [Related]
3. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
4. IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients.
Echeverría N; Chiodi D; López P; Sanchez Ciceron A; Angulo J; López-Lastra M; Silvera P; Canavesi A; Bianchi C; Colistro V; Cristina J; Hernandez N; Moreno P
Virol J; 2018 Mar; 15(1):40. PubMed ID: 29499724
[TBL] [Abstract][Full Text] [Related]
5. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
Halfon P; Bourliere M; Ouzan D; Maor Y; Renou C; Wartelle C; Pénaranda G; Tran A; Botta D; Oules V; Castellani P; Portal I; Argiro L; Dessein A
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):931-5. PubMed ID: 21900787
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.
Abe H; Tsubota A; Shimada N; Atsukawa M; Kato K; Takaguchi K; Asano T; Chuganji Y; Sakamoto C; Toyoda H; Kumada T; Ide T; Sata M; Aizawa Y
Hepatol Res; 2015 Apr; 45(4):387-96. PubMed ID: 24849518
[TBL] [Abstract][Full Text] [Related]
7. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
9. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
Lindh M; Lagging M; Arnholm B; Eilard A; Nilsson S; Norkrans G; Söderholm J; Wahlberg T; Wejstål R; Westin J; Hellstrand K
J Viral Hepat; 2011 Jul; 18(7):e325-31. PubMed ID: 21692944
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection.
Kitson MT; George J; Dore GJ; Leung R; Button P; McCaughan GW; Grawford DH; Siebert W; Weltman MD; Cheng WS; Roberts SK
J Gastroenterol Hepatol; 2014; 29(7):1458-62. PubMed ID: 25587616
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
13. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent.
Ranjan P; Fletcher GJ; Radhakrishnan M; Sivakumar J; Premkumar PS; Goel A; Zachariah UG; Abraham P
Indian J Med Microbiol; 2016; 34(3):335-41. PubMed ID: 27514956
[TBL] [Abstract][Full Text] [Related]
14. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
[TBL] [Abstract][Full Text] [Related]
17. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
[TBL] [Abstract][Full Text] [Related]
18. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
Pol S; Aerssens J; Zeuzem S; Andreone P; Lawitz EJ; Roberts S; Younossi Z; Foster GR; Focaccia R; Horban A; Pockros PJ; Van Heeswijk RP; De Meyer S; Luo D; Botfield M; Beumont M; Picchio G
J Hepatol; 2013 May; 58(5):883-9. PubMed ID: 23321318
[TBL] [Abstract][Full Text] [Related]
19. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
